ADH 1
Alternative Names: ADH-1; ADH-100001; ExherinLatest Information Update: 24 Oct 2021
At a glance
- Originator McGill University
- Developer Adherex Technologies
- Class Antineoplastics; Cyclic peptides; Oligopeptides
- Mechanism of Action Angiogenesis inhibitors; Cadherin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Solid tumours
Most Recent Events
- 22 Apr 2009 Preclinical drug interactions data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
- 02 Jun 2008 Interim efficacy data from a phase I trial in Malignant melanoma released by Adherex Technologies
- 19 May 2008 Interim efficacy data from a phase I/II trial in malignant melanoma released by Adherex